Drugs / Lacripep
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03226444 | Jun 2017 → Dec 2019 | Sjogren syndrome, dry eye syndrome | TearSolutions, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07568730 | Feb 2026 → Feb 2027 expected | neurotrophic keratopathy | TearSolutions, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06854393 | May 2025 → Jun 2027 expected | corneal disorder | Henry M. Jackson Foundation for the Advancement of Military Medicine | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-02 | TearSolutions, Inc. | Regulatory TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed tearsolutions.com ↗ |
| 2022-09-28 | TearSolutions, Inc. | Results TearSolutions, Inc., Announces Results From First-In-Human Clinical Trial published in Cornea tearsolutions.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-02 | TearSolutions, Inc. | TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed tearsolutions.com ↗ |
| 2022-09-28 | TearSolutions, Inc. | TearSolutions, Inc., Announces Results From First-In-Human Clinical Trial published in Cornea tearsolutions.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lacripep | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07568730 ↗ |
| Route | Topical | “0.005% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.” NCT03226444 ↗ |